Design, synthesis and biological activities of novel pleuromutilin derivatives with a substituted triazole moiety as potent antibacterial agents

Zhe Zhang,Kang Li,Guang-Yu Zhang,You-Zhi Tang,Zhen Jin
DOI: https://doi.org/10.1016/j.ejmech.2020.112604
IF: 7.088
2020-10-01
European Journal of Medicinal Chemistry
Abstract:<p>A series of novel pleuromutilin derivatives possessing 1,2,3-triazole moieties were synthesized via click reactions under mild conditions. The <em>in vitro</em> antibacterial activities of these derivatives against 4 strains of <em>S. aureus</em> (MRSA ATCC 43300, ATCC 29213, AD 3, and 144) and 1 strain of <em>E. coli</em> (ATCC 25922) were tested by the broth dilution method. The majority of the synthesized derivatives displayed potent antibacterial activities against MRSA (MIC = 0.125 ∼ 2 μg/mL). It was also found that most compounds had no significant inhibitory effect on the proliferation of RAW264.7 cells at the concentration of 8 μg/mL. Among these derivatives, compound <strong>32</strong> (∼1.71 log<sub>10</sub> CFU/g) containing dimethylamine group side chain displayed more effective than tiamulin (∼0.77 log<sub>10</sub> CFU/g) at the dose of 20 mg/kg in reducing MRSA load in thigh infected mice. Additionally, compound <strong>32</strong> (the survival rate was 50%) also displayed superior <em>in vivo</em> efficacy to that of tiamulin (the survival rate was 20%) in the mouse systemic model. Structure-activity relationship (SAR) studies resulted in compound <strong>32</strong> with the most potent <em>in vitro</em> and <em>in vivo</em> antibacterial activity among the series. Moreover, compound <strong>32</strong> was evaluated in CYP450 inhibition assay and showed moderate <em>in vitro</em> inhibition of CYP3A4 (IC<sub>50</sub> = 6.148 μM).</p>
chemistry, medicinal
What problem does this paper attempt to address?